"I also would like to state that your directors each intend to take up their maximum allocation under the rights issue, but on top of this, we have also underwritten an extra $900,000 in case there is a shortfall. Your directors hope that this show of support of the company by the directors will send a clear and loud message to the market that your directors have great expectations that our burette technology will shortly be successful in the global burette market. A market that is estimated to be worth $3.3 billion."
"On the 12th May, 2011 Analytica Limited (ASX:ALT) and Medical Australia Limited announced a Supply Agreement with the New South Wales Ambulance Service and that the first order has been completed under the distribution agreement signed in April 2010."
"This contract represents an excellent starting point for the commercialisation of this technology. Having our First Flow Burette aboard ambulances provides excellent exposure of the device to clinicians and nurses across the state as patients arrive at emergency wards with the device connected."
"Another major NSW Hospital evaluation is scheduled for the New Year and the First Flow is also currently being evaluated by a major Queensland hospital. The Autoflush feature is also on track to be introduced into the Tuta burettes with tooling completed and validated. We anticipate the release early in the New Year."
ALT Price at posting:
3.0¢ Sentiment: Buy Disclosure: Held